Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00001057 · ClinicalTrials.gov registry record · Phase 2

The Effectiveness of Two Anti-HIV Treatments in HIV-Infected Patients

A Phase 2 study of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

Completed
Registry status
Phase 2
Development phase
105
Enrollment target
7
Study locations

NCT00001057: Completed Phase 2 study of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

NCT00001057 is a Phase 2 study of HIV Infections that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 105 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (76% lower). The trial reports 7 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00001057, a Phase 2 study of HIV Infections, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

COMPLETED
Registry status
Phase 2
Development phase
105 participants
Enrollment target
7
Study locations

Study Summary

To determine the effects of zidovudine (AZT) alone and in combination with didanosine (ddI) on viral load in the lymphoid tissue and blood of antiretroviral-naive, HIV-infected patients with CD4 counts greater than or equal to 550 cells/mm3. Recent studies have shown that during the asymptomatic phase (clinical latency) of HIV infection, there is an extraordinarily large number of infected CD4+ lymphocytes and macrophages throughout the lymphoid system, both in latent and productive states. These findings support the belief that early intervention therapy with reverse transcriptase inhibitors could prolong the clinical latency period.

Conditions Studied

Interventions

  • DRUG Zidovudine
  • DRUG Didanosine

Study Locations (7)

Minnesota

  • Hennepin County Med Clinic - Minneapolis
  • Univ of Minnesota - Minneapolis
  • St Paul Ramsey Med Ctr - Saint Paul

Nebraska

  • Univ of Nebraska Med Ctr - Omaha

Ohio

  • Case Western Reserve Univ - Cleveland

Pennsylvania

  • Thomas Jefferson Univ Hosp - Philadelphia

Texas

  • Univ of Texas Galveston - Galveston

Trial Details

FieldValue
Enrollment Target 105 participants
Est. Completion 1995-05
Phase Phase 2

What the finished NCT00001057 record still lists

NCT00001057 is an interventional study that assigns participants to a tested intervention. The registered 105 participants enrollment target is mid-sized for trials with a published cap, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (76% lower).

The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 2 interventions - of which Zidovudine is the first listed.

NCT00001057 lists 7 locations in 5 states (Minnesota, Nebraska, Ohio).

Frequently Asked Questions

What is clinical trial NCT00001057 about?

NCT00001057 is a clinical study titled "The Effectiveness of Two Anti-HIV Treatments in HIV-Infected Patients". To determine the effects of zidovudine (AZT) alone and in combination with didanosine (ddI) on viral load in the lymphoid tissue and blood of antiretroviral-naive, HIV-infected patients with CD4 counts greater than or equal to 550 cells/mm3. Recent studies have shown that during the asymptomatic ph...

What is the current status of trial NCT00001057?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 105 participants. Estimated completion is 1995-05.

What conditions does trial NCT00001057 study?

This clinical trial studies the following conditions: HIV Infections.

What interventions are being tested in trial NCT00001057?

The interventions under investigation include: Zidovudine (DRUG), Didanosine (DRUG).

Who is sponsoring clinical trial NCT00001057?

This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00001057 being conducted?

This trial has 7 study locations across Minnesota, Nebraska, Ohio, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00001057's enrollment target sits among peer trials

105 259th of 542 higher than 283 of 542 other HIV Infections trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03372317 · 105 participants

    Tau PET in Imaging and Cognition: Healthy Adults From 55-90

  • NCT04253964 · 105 participants · Phase 2

    Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy

  • NCT04742452 · 105 participants · NA

    Comparison of Partial Rotator Cuff Repair vs. Superior Capsular Reconstruction for Irreparable Rotator Cuff Tears

  • NCT04875429 · 105 participants · NA

    Zenith® Fenestrated+ Clinical Study

Source: ClinicalTrials.gov NCT00001057, the US trial registry maintained by the National Library of Medicine. NCT00001057 (mid enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.